Generics maker Laurus Lab’s net profit more than doubles in Q1 on strong CDMO business growth
Within CDMO, small molecules segment grew 69% to ₹835 crore, driven by growth in late-stage clinical and commercial Active Pharmaceutical Ingredient (API) supplies. Revenue from the Bio (large molecules) segment were up 21% to ₹35 crore.Generics division revenue increased 10% YoY to ₹1,156 crore.Laurus Labs Executive Director and CFO V. Ravi Kumar said the company delivered a strong operating performance in Q1 despite challenging macroeconomic volatility.There was sustained momentum across both CDMO and affordable medicine (generics) divisions.
- ▪Within CDMO, small molecules segment grew 69% to ₹835 crore, driven by growth in late-stage clinical and commercial Active Pharmaceutical Ingredient (API) supplies.
- ▪Revenue from the Bio (large molecules) segment were up 21% to ₹35 crore.Generics division revenue increased 10% YoY to ₹1,156 crore.Laurus Labs Executive Director and CFO V.
- ▪Ravi Kumar said the company delivered a strong operating performance in Q1 despite challenging macroeconomic volatility.There was sustained momentum across both CDMO and affordable medicine (generics) divisions.
The Hindu publishes from India and files mainly under world. We currently carry 653 of its stories.
Opening excerpt (first ~120 words) tap to expand
Generic drugmaker Laurus Labs’ consolidated net profit more than doubled year-on-year (YoY) to ₹361.99 crore for the June quarter, driven by a 29% jump in revenue.Revenue from operations rose to ₹2,026.31 crore, supported by a 67% surge in CDMO (Contract Development and Manufacturing Organization) business to ₹870 crore. Within CDMO, small molecules segment grew 69% to ₹835 crore, driven by growth in late-stage clinical and commercial Active Pharmaceutical Ingredient (API) supplies. Revenue from the Bio (large molecules) segment were up 21% to ₹35 crore.Generics division revenue increased 10% YoY to ₹1,156 crore.Laurus Labs Executive Director and CFO V. V.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hindu.
Discussion
0 commentsMore from The Hindu
